TY - JOUR T1 - Cancer screening practices of cancer survivors JF - Canadian Family Physician JO - Can Fam Physician SP - 980 LP - 986 VL - 58 IS - 9 AU - Eva Grunfeld AU - Rahim Moineddin AU - Nadia Gunraj AU - M. Elisabeth Del Giudice AU - David C. Hodgson AU - Janice S. Kwon AU - Laurie Elit Y1 - 2012/09/01 UR - http://www.cfp.ca/content/58/9/980.abstract N2 - Objective To describe cancer screening rates for cancer survivors and compare them with those for matched controls. Design Population-based, retrospective study with individuals linked across administrative databases. Setting Ontario. Participants Survivors of breast (n = 11 219), colorectal (n = 4348), or endometrial (n = 3473) cancer, or Hodgkin lymphoma (HL) (n = 2071) matched to general population controls. Survivors were those who had completed primary treatment and were on “well” follow-up. The study period was 4 years (1 to 5 years from the date of cancer diagnosis). Main outcome measures Never versus ever screened (in the 4-year study period) for breast cancer, colorectal cancer (CRC), and cervical cancer and never versus ever received (during the study period) a periodic health examination; rates were compared between cancer survivors and controls. Random effects models were used to estimate odds ratios and 95% CIs. Results Sixty-five percent of breast cancer survivors were never screened for CRC and 40% were never screened for cervical cancer. Approximately 50% of CRC survivors were never screened for breast or cervical cancer. Thirty-two percent of endometrial cancer survivors were never screened for breast cancer and 66% were never screened for CRC. Forty-four percent of HL survivors were never screened for breast cancer, 77% were never screened for CRC, and 32% were never screened for cervical cancer. Comparison with matched controls showed a mixed picture, with breast and endometrial cancer survivors more likely, and CRC and HL survivors less likely, than controls to be screened. Conclusion There is concern about the preventive care of cancer survivors despite frequent visits to both oncology specialists and family physicians during the “well” follow-up period. ER -